JP2023553253A - 重水素化jak阻害剤による脱毛障害の治療のためのレジメン - Google Patents

重水素化jak阻害剤による脱毛障害の治療のためのレジメン Download PDF

Info

Publication number
JP2023553253A
JP2023553253A JP2023526173A JP2023526173A JP2023553253A JP 2023553253 A JP2023553253 A JP 2023553253A JP 2023526173 A JP2023526173 A JP 2023526173A JP 2023526173 A JP2023526173 A JP 2023526173A JP 2023553253 A JP2023553253 A JP 2023553253A
Authority
JP
Japan
Prior art keywords
day
compound
period
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553253A5 (cg-RX-API-DMAC7.html
Inventor
カセラ,ジェームズ・ヴィ.
Original Assignee
サン ファーマシューティカル インダストリーズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サン ファーマシューティカル インダストリーズ,インコーポレイテッド filed Critical サン ファーマシューティカル インダストリーズ,インコーポレイテッド
Publication of JP2023553253A publication Critical patent/JP2023553253A/ja
Publication of JP2023553253A5 publication Critical patent/JP2023553253A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023526173A 2020-10-28 2021-10-28 重水素化jak阻害剤による脱毛障害の治療のためのレジメン Pending JP2023553253A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US63/106,790 2020-10-28
US202163155637P 2021-03-02 2021-03-02
US63/155,637 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
JP2023553253A true JP2023553253A (ja) 2023-12-21
JP2023553253A5 JP2023553253A5 (cg-RX-API-DMAC7.html) 2024-11-01

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526173A Pending JP2023553253A (ja) 2020-10-28 2021-10-28 重水素化jak阻害剤による脱毛障害の治療のためのレジメン

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516684A (ja) * 2016-05-04 2019-06-20 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化jak阻害剤による脱毛障害の処置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516684A (ja) * 2016-05-04 2019-06-20 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化jak阻害剤による脱毛障害の処置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OLSEN, E. A. ET AL.: "Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, random", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 82, no. 2, JPN6025045027, 2019, pages 412 - 419, ISSN: 0005722985 *
ROSMARIN, D. ET AL.: "Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial", THE LANCET, vol. 396, JPN6025045026, 2020, pages 110 - 120, ISSN: 0005722986 *

Also Published As

Publication number Publication date
MX2023005027A (es) 2023-07-31
AU2021372512A1 (en) 2023-06-22
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
CA3196551A1 (en) 2022-05-05
CL2023001201A1 (es) 2023-11-17
IL302401A (en) 2023-06-01
DOP2023000085A (es) 2023-07-31
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
JOP20230090A1 (ar) 2023-04-27
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
JP7586868B2 (ja) 重水素化jak阻害剤による脱毛障害の処置
US20230390292A1 (en) Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
JP2024531188A (ja) 重水素化jak阻害剤による脱毛障害の治療
AU2024360854B2 (en) Method of treating hair loss disorders
JP2025515051A (ja) 重水素化jak阻害剤による治療のための投与レジメン
OA21444A (en) Regimens For The Treatment Of Hair Loss Disorders With Deuterated Jak Inhibitors.
CN116916927A (zh) 用于用氘化jak抑制剂治疗脱发症的方案
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260602